Key Facts Surrounding This News Item
- CKPT had returned +44.33% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.
More Info About Checkpoint Therapeutics, Inc. (CKPT)
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. View our full CKPT ticker page with ratings, news, and more.
Try StockNews.com Premium Today!
Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!